Summit Therapeutics
SMMT
55 hedge funds and large institutions have $13.6M invested in Summit Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 8 closing their positions.
165% more call options, than puts
Call options by funds: $135K | Put options by funds: $51K
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 54 → 55 (+1)
0.05% more ownership
Funds ownership: 11.32% → 11.37% (+0.05%)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
42% less capital invested
Capital invested by funds: $23.3M → $13.6M (-$9.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$962K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$623K |
| 3 |
Morgan Stanley
New York
|
+$386K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$205K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$93.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$1.37M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$445K |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$146K |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$72K |
| 5 |
SG Americas Securities
New York
|
-$50.6K |
SMMT Hedge Fund Activity: Q4 2021 in Review
55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2021, worth a combined $13.6M — down 42% from $23.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SMMT positions and 8 closed out — a net gain of 1 holder — while 16 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $962K. The largest seller was Polar Capital Holdings, cutting an estimated $1.37M.
- 55 institutional investors held Summit Therapeutics (SMMT) as of Q4 2021, up from 54 in Q3 2021.
- Funds reported $13.6M of Summit Therapeutics stock for Q4 2021, down 42% quarter-over-quarter.
- 9 funds opened new Summit Therapeutics positions in Q4 2021 and 8 closed out, a net change of +1 holder.
- The largest Summit Therapeutics buyer in Q4 2021 was BlackRock, an estimated $962K added.
- The largest Summit Therapeutics seller in Q4 2021 was Polar Capital Holdings, an estimated $1.37M sold.
Based on aggregated 13F filings for Q4 2021.